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ABSTRACT
Objective: To review the evidence for the association
of breast feeding, breastfeeding duration or the timing
of gluten introduction and the later development of
celiac disease (CD).
Design: Systematic review.
Methods: We searched MEDLINE, via PubMed,
EMBASE and Web of Science, for studies published up
to 31 August 2015 investigating the association of
breastfeeding duration, breast feeding at the moment
of gluten introduction or the timing of gluten
introduction and the later development of CD.
Prospective studies had to enrol infants/children at
high risk of CD. For retrospective studies, participants
had to be children or adults with CD. The paper quality
was assessed by means of a GRADE score and the
bias risk was assessed by the Newcastle-Ottawa Scale
(for observational cohort studies) and Cochrane
Collaboration’s tool (for randomised trials).
Results: Out of 149 retrieved papers, 48 were
considered in depth and 16 were included in this
review (9 were prospective and 2 were interventional).
We found that neither duration of breastfeeding nor
breastfeeding at time of gluten introduction nor the
delayed introduction of gluten during weaning were
effective in preventing later development of CD.
Conclusions: Currently, there is no evidence on the
optimal breastfeeding duration or the effects of
avoiding early (<4 months of age) or late (≥6 or even
at 12 months) gluten introduction in children at risk of
CD. Accordingly, no specific general recommendations
about gluten introduction or optimal breastfeeding
duration can be presently provided on evidence-based
criteria in order to prevent CD.
INTRODUCTION
Celiac disease (CD) is a permanent immune-
mediated enteropathy, triggered in genetic-
ally predisposed individuals by gluten.
Gluten is a protein fraction of cereals, such
as wheat, rye and barley. The genetic predis-
position consists in the presence of alleles
encoding for the molecules DQ2 or DQ8 of
the human leucocyte antigen (HLA).1–3
CD is probably the best known multifactor-
ial disease. Genetic predisposition and
gluten intake are both necessary, but not suf-
ﬁcient for the development of this condition.
Only roughly 5% of the DQ2/8+ worldwide
population will eventually develop CD.4
Therefore, other factors are expected to be
involved in CD pathogenesis. Among these,
additional genes are increasingly being
recognised; but repeated viral infections,
modality of delivery, imbalance of the intes-
tinal microbiota and infant feeding practices
have also been hypothesised.5–8
The hypothesis of inducing, via early
feeding practices, oral tolerance to gluten in
infants at genetic risk for CD, has been long
investigated. Both prolonged breast feeding
and gluten introduction during a sensitive
‘window’ period, in which the infant’s
immune system is more likely to adapt to
food antigens, have been assumed as protect-
ive factors towards the development of CD.8
The epidemiological evidence about this
strategy for the primary prevention of CD is
conﬂicting and deﬁnitive recommendations
on early feeding in children at genetic risk
for CD are not available.
The aim of this paper is, therefore, to sys-
tematically review all the related published
clinical trials and cohort studies, in order to
Strengths and limitations of this study
▪ Our systematic review offers an inclusive over-
view of the population-based evidence regarding
infant feeding practices and the risk of develop-
ing celiac disease (CD).
▪ A study quality score and a bias risk scale are
used to appraise the clinical transferability of
each study included in this systematic review.
▪ A small number of prospective clinical trials are
available about the role of breast feeding and the
gluten introduction during weaning. The majority
of the studies were retrospective and enrolled
children not at genetic risk for CD.
▪ No specific general recommendations about
gluten introduction or optimal breastfeeding dur-
ation can be presently provided on evidence-
based criteria in order to prevent CD. A possible
exception might be DQ2 homozygous girls, in
whom an early introduction of gluten appears to
be associated with a greater risk of subsequent
development of CD.
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assess whether: (1) breastfeeding practice and breast-
feeding duration protects from the development of CD;
(2) breast feeding at time of gluten introduction exerts
a protective effect on CD risk; (3) timing of gluten intro-
duction may have a role in triggering CD; (4) the
amount of gluten during the complementary feeding
period plays a role in the onset of CD. These evidences
are then critically discussed to assess the appropriate
timing of ﬁrst gluten introduction during weaning, also
in the light of the role of the other environmental
variables.
MATERIALS AND METHODS
Search strategy
A systematic review of the literature was initially per-
formed in November 2014, and then repeated in
December 2014 and on 1 September 2015. The search
was carried out in the content of MEDLINE, via
PubMed (http://www.ncbi.nlm.nih.gov/pubmed)
EMBASE and Web of Science, following guidelines from
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) group. Letters to the
editor, abstracts and proceedings from scientiﬁc meet-
ings were excluded from the analysis. Only papers in
English were considered. Two authors (MS and CA)
independently selected the articles, and retrieved and
assessed the potentially relevant ones. Discrepancies in
article selection were resolved by a face-to-face discus-
sion; if the discrepancy stood, a third researcher was
consulted (YS). The following search terms were used:
(‘celiac’ OR ‘coeliac’ OR ‘sprue’ OR ‘gluten enterop-
athy’) and (breast-feeding OR breastfeeding OR breast
feeding OR breastfed); (‘celiac’ OR ‘coeliac’ OR ‘sprue’
OR ‘gluten enteropathy’) and (‘weaning’ OR ‘comple-
mentary feeding’); (‘gluten’) and (‘time OR timing’)
and (‘introduction’); (‘gluten’) and (‘infant feeding’)
(‘celiac’ OR ‘coeliac’ OR ‘sprue’ OR ‘gluten enterop-
athy’) and (‘infant feeding’).
Inclusion criteria
Types of study
Any type of study on humans, reporting primary data,
was included in this systematic review. Previous systematic
reviews and meta-analyses were excluded.
Types of participants
The prospective studies had to enrol infants/children at
increased risk of developing CD. Risk of developing CD
was intended as deﬁned by HLA DQ2/8 positivity and/
or at least a ﬁrst-degree relative with CD or type 1 dia-
betes mellitus (T1DM). For retrospective studies, partici-
pants had to be children or adults with CD diagnosed by
small bowel biopsy or serological positivity (anti-tissue
transglutaminase (tTG) antibodies).
To be included in this analysis, the studies should have
assessed the risk of CD in people who were:
▸ Ever breast fed compared with those never breast fed;
▸ Breast fed for different periods of time;
▸ Breast fed at the time of the ﬁrst gluten introduction
during weaning compared with those who were not;
▸ Receiving gluten for the ﬁrst time during weaning at
different ages.
Outcome measures
The primary outcome measures were the development
of CD-associated autoimmunity (anti-tTG antibodies)
and/or biopsy-proven CD.
Data collection, extraction and analysis
An initial evaluation of the title, abstract and keywords
of every record found was performed by MS and CA.
The next step was the retrieval of the full text of poten-
tially relevant trials. The two reviewers independently
assessed the eligibility of each potentially relevant trial
with the use of inclusion criteria. If they had different
opinions, these were resolved by discussion with the
third reviewer (YS).
The information extracted included the following: (1)
general characteristics of the studies (ﬁrst author and
year of publication of the article, country, number and
age of the participants, inclusion and exclusion criteria;
(2) design and characteristics of the data collection and
eventual intervention; (3) deﬁnition of the outcome
(CD diagnosis, autoimmunity); and (4) main results.
Main summary measure was considered HR/OR.
Study quality
In order to appraise the quality of the studies included
in this review, we used the GRADE score ranging from 0
(minimum) to 4 (maximum) points. GRADE is a system-
atic and explicit approach to making judgements about
quality of evidence, based on a score given to each study
according to the following parameters: study design
(prospective or observational), allocation process,
follow-up, withdrawals, directness consistency and effect
size.9
ASSESSMENT OF RISK OF BIAS
For observational cohort studies, we used the
Newcastle-Ottawa Scale to assess the risk of bias.10 This
scale uses a star system (with a maximum of nine stars)
to evaluate a study in three domains: selection of partici-
pants, comparability of study groups and the ascertain-
ment of outcomes of interest. We judged studies that
received a score of nine stars to be at low risk of bias,
studies that scored seven or eight stars to be at medium
risk and those that scored six or less to be at high risk of
bias. Similarly, for the randomised trials, we used the
Cochrane Collaboration’s tool for assessing the risk of
bias.11 This tool evaluates seven possible sources of bias:
random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of
outcome assessment, incomplete outcome data, selective
reporting and other bias. For each individual domain,
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we classiﬁed studies into low, unclear and high risk of
bias.
RESULTS
Studies included in the review
Our systematic search through MEDLINE, EMBASE and
Web of Science retrieved 149 papers. Of them, 48
papers were potentially considered eligible for inclusion.
We obtained the full text of those papers and, after the
exclusion of 20 review articles, a commentary and a
letter, 11 original research articles were also excluded
because they did not meet the inclusion criteria. In
detail, the reasons for exclusion were as follows: absence
of data about breastfeeding duration and/or the age of
gluten introduction, no CD diagnosis or CD auto-
immunity as outcome of the study and lack of negative/
healthy controls. Thus, 16 papers reporting the results
of 16 different studies were included in the analysis.
Of the 16 studies included in this review, nine were
prospective (two interventional and seven observa-
tional). The interventions consisted of the prescription
of gluten introduction (no indication about the
amount) at 6 or 12 months of age in the CeliPrev
Study12 and the daily administration of 100 mg of gluten
at 16–24 weeks of age in the PreventCD study,13
respectively.
Three studies were based on populations of children
at genetic risk of T1DM.14–16 Three studies had a multi-
centric study design.12 13 16 Most papers (13) were from
Europe, with 3 from Italy,12 17 18 4 from Sweden,19–22 3
from Germany14 23–24 and 1 each from the UK,25
Norway26 and the Netherlands;27 1 was multicentric with
groups from Europe and the USA,16 and 1 was a
European study funded by the seventh European
research framework programme.13 The remaining study
was from the USA.15
Breast feeding and risk of CD
Ten of the 16 papers investigating the effect of breast
feeding on the risk of CD concluded that the duration of
breast feeding did not show a preventive effect on the
development of CD. These studies included the most
recent and consequently those with the highest quality
score, represented by the two randomised interven-
tional12 13 as well as eight of the nine prospective studies
considered in the analysis.14–16 22–27 One of these studies
even found a positive correlation between prolonged
breast feeding for over the ﬁrst year of age and the
increased incidence of CD, although the statistical signiﬁ-
cance of this association was only minimal.26 A protective
effect of breast feeding on the later development of CD
was reported by four retrospective papers (table 1).17–19 23
Breast feeding at gluten introduction and CD
Nine of the 16 studies included in this review examined
the effect of breast feeding at the time of gluten intro-
duction on later development of CD (table 2). Among
these, two retrospective studies, enrolling individuals
whose genetic background was not studied, as controls,
found a preventive effect of being breast fed at the ﬁrst
ingestion of gluten during the introduction of solid
foods, with a relevant statistical signiﬁcance (OR ranging
from 0.35 to 0.55).19 23
However, none of the six prospective papers did not
report such a protective effect.12 13 15 16 21 26 This group
of studies includes the most recent study as well as those
with the highest quality score, characteristically includ-
ing children with a common genetic background (pre-
disposing to a risk for CD or T1DM or DQ2/8+ positive
children).
Time of gluten introduction and CD
Eight of the 11 papers reporting information about the
time of gluten introduction did not ﬁnd any correlation
between the age of the children at this stage and devel-
opment of CD (table 3). The recent paper by Lionetti
et al12 concluded that there is no difference in CD inci-
dence at 5 years of age in children who have gluten
introduced at 6 months compared with those who have
consumed gluten for the ﬁrst time at 12 months (HR
0.9; 95% CI 0.6 to 1.4). Also, no difference in the inci-
dence of CD between the two groups, by stratifying the
children for the genetic risk (homozygosis or heterozy-
gosis for the DQ2), resulted in this study.
These results were similar to those simultaneously
reported by a recent survey that found a similar CD inci-
dence at 3 years of age in children who received a daily
dose of 100 mg of gluten between 16 and 24 weeks of
age and the children who began receiving gluten at
24 weeks (1.23; 95% CI 0.79 to 1.91).13 Likewise, the R
generation study concluded that there was no difference
in the development of CD autoimmunity whether gluten
is introduced before or after 6 months of age.27
The results of both these studies are in agreement
with the conclusions of the most recent paper, which
reports the results of the multicentric TEDDY study.
According to this study, neither the early (<17 weeks)
nor the delayed introduction of gluten-containing
cereals (>26 weeks) is a risk factor for the later develop-
ment of CD-associated autoimmunity and biopsy-proven
CD.16
On the contrary, the Norwegian study reported a
slightly increased risk for children introduced to gluten
when complementary feeding was started after 6 months
of age (OR 1.27; 95% CI 1.01 to 1.65), but not for those
receiving gluten before 4 months of age.26 Only one
paper described an increased risk of developing
CD-related autoimmunity in two groups of children
introduced to gluten earlier and later, respectively, than
the reference period (4–7 months of age).15 However,
the signiﬁcance for the group exposed to gluten after
7 months of age was very narrow, with a HR of 1.87
(95% CI 0.97 to 3.60), while the ﬁvefold risk shown by
children introduced to gluten before 3 months of age
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Table 1 Effect of BF and duration of BF on the development of CD
Reference
Number of infants/children
enrolled
Length of
observation Effect of BF Effect size
GRADE
score
Bias
risk
Retrospective studies
Auricchio et al17 Biopsy-proven CD=216
controls=289
NA BF >30 days protective OR 4.05 (95% CI 2.2 to
7.2)
2 High
Greco et al18 Biopsy-proven CD=201
controls=1949
NA BF <90 days protective OR 4.97 (95% CI 3.5 to
6.9)
2 High
Fälth-Magnusson
et al19
Biopsy-proven CD=72
controls=264
NA BF >2.5 months protective p<0.0002 2 High
Ascher et al20 85 (8 found to have silent CD at
biopsy)
NA No effect of duration of BF on CD
development
6.5 months for cases vs
5.0 months for controls
p ns
2 High
Peters et al23 Biopsy-proven CD=143
controls=137
NA BF >2 months protective OR 0.37 (95% CI 0.21
to 0.64)
1 High
Roberts et al25 Biopsy-proven CD=90
controls=248 521
NA None 22 vs 38; p=0.28 1 High
Decker et al24 Biopsy-proven CD=157
controls=862
Up to a mean age
of 13.9 years
None OR 0.93 (95% CI 0.69
to 1.25)
1 High
Prospective studies
Ivarsson et al21 Biopsy-proven CD=627
controls=1254
NA Protective when CD diagnosis made in
patients <2 years; none for CD
diagnosis made in patients <2 years
p<0.001
p NS
2 High
Ziegler et al14 1610 (27 developed CD
autoimmunity*)
From birth to
12 years of age
None 0–3 months OR
0.88 (95% CI 0.2 to 2.7)
3.1–6 months OR 1.2
(95% CI 0.4 to 3.6)
>6 months OR 1.00
(reference)
3 Medium
Norris et al15 1560 (51 developed CD
autoimmunity*)
From birth to
10 years of age
None 1.02 (95% CI 0.99 to
1.05)
3 Medium
Welander et al22 Biopsy-proven CD=44
controls=936
At 10 years of
age
None 0–2 months OR 0.7
(95% CI 0.2 to 3.1)
3–4 months OR 0.7
(95% CI 0.2 to 3.2)
5–6 months OR 0.3
(95% CI 0.0 to 2.1)
7–8 months OR
1.4 (95% CI 0.7 to 3.1)
9–10 months OR 1.3
(95% CI 0.6 to 2.8)
11–12 OR 1.00
(reference)
3 High
Continued
4
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Table 1 Continued
Reference
Number of infants/children
enrolled
Length of
observation Effect of BF Effect size
GRADE
score
Bias
risk
Størdal et al26 Biopsy-proven CD=324
controls=81 834
From birth to
12 years of age
BF >1 year predisposing <6 months reference
6–12 months OR 1.27
(95% CI 0.85 to 1.86)
>13 months OR 1.49
(95% CI 1.01 to 2.21)
3 High
Jansen, 201427 1679 (43 developed CD
autoimmunity*)
At 6 years of age No difference in proportion of BF
children in group who developed or do
not have autoimmunity
p ns 3 Medium
Vriezinga et al13 944 (105 developed CD
autoimmunity*, out of them 77
biopsy-proven overt CD)
From birth to
3 years of age
None Overt CD
0 months OR 0.90 (95%
CI 0.22 to 3.6)
<3 months OR 1.3 (95%
CI 0.41 to 4.1)
4–5 months OR 1.5
(95% CI 0.57 to 4.1)
>6 months OR 1.2 (95%
CI 0.67 to 2.2)
4 Low
Lionetti et al12 832 (117 developed CD
autoimmunity,* out of them 86
biopsy-proven overt CD)
From birth to
10 years of age
None CD autoimmunity
OR=1.0 (95% CI 0.9 to
1.0)
Overt CD
OR=1 (95% CI 0.9 to
1.1)
4 Low
*Serological positivity of tTG antibodies.
BF, breast feeding; CD, celiac disease; NA, not available; NS, not significant; tTG, tissue transglutaminase.
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had more robust statistical signiﬁcance (HR 5.17, 95%
CI 1.44 to 18.57).
Amount of gluten at weaning and development of CD
None of the papers included in our analysis compared
the effect of different amount of gluten given to chil-
dren during weaning on the risk of CD. This aspect is
mostly unknown and the scant available data come from
a Swedish experience. However, papers reporting the
paradigmatic Swedish experience were excluded from
the analysis, since negative controls were not included in
the description.28
DISCUSSION
Breast feeding and CD
Our review shows that some studies reported a protective
effect of breast feeding on the risk of developing CD
while others, on the contrary, reported no effect. The
latter are the most recent, and have the highest GRADE
score and the lowest bias risk. Accordingly, all the pro-
spective studies included in our analysis, except one,
concluded that the duration of breast feeding (exclusive
and/or complementary) and/or gluten introduction
while the infant is still breast fed had no impact on the
risk of developing CD. In addition, the only prospective
study to describe a protective effect of breast feeding,
reported this effect only in the group of children diag-
nosed with CD below 2 years of age and not for those
diagnosed over this age. These conclusions contrasted
with the meta-analysis by Akobeng et al,29 which
reported protection against CD with longer duration of
breast feeding, based on the ﬁndings from ﬁve earlier
retrospective studies (OR 0.48; 95% CI 0.40 to 0.59). So,
the limited effect of breast feeding found may only rep-
resent a delay of the development of the symptoms and
clinical signs of CD, rather than being a real prevention
of this condition.
This result is quite surprising, since earlier studies and
reviews indicated a potential protective effect on CD
Table 2 Effect of BF at the time of gluten introduction on the development of CD
Reference
Number of infants/children
enrolled
Effect of BF
during gluten
introduction Effect size
GRADE
score
Bias
risk
Retrospective studies
Fälth-Magnusson et al19 Biopsy-proven CD=72
controls=264
Protective OR 0.35 (95% CI
0.17 to 0.66)
2 High
Ascher et al20 85 (8 found to have silent CD
at biopsy)
None NS 2 High
Peters et al23 Biopsy-proven CD=143
controls=137
Protective OR 0.46 (95% CI
0.27 to 0.78)
1 High
Prospective studies
Ivarsson et al21 Biopsy-proven CD=627
controls=1254
Protective OR 0.55 (95% CI
0.4 to 0.77)
2 High
Norris et al15 1560 (51 developed CD
autoimmunity*)
None OR=1.32 (95%
CI 0.76 to 2.28)
3 Medium
Størdal et al26 Biopsy-proven CD=324
controls=81 834
None BF >1 months
after introduction
OR 1.17 (95% CI
0.74 to 1.87)
BF <1 months
after introduction
OR 0.65 (95% CI
0.37 to 1.14)
3 High
Vriezinga et al13 944 (105 developed CD
autoimmunity,* out of them 77
biopsy-proven overt CD)
None OR=1.35 (95%
CI 0.57 to 4.1)
4 Low
Lionetti et al12 832 (117 developed CD
autoimmunity,* out of them 86
biopsy-proven overt CD)
One CD autoimmunity
OR=1.5 (95% CI
0.77 to 3.0)
Overt CD
OR=1 (95% CI
0.6 to 2.3)
4 Low
Aronsson et al16 6434 (773 developed
autoimmunity,* 307 overt
biopsy-proven CD)
None Overt CD
OR=1.13 (95%
CI 0.88 to 1.46)
3 Medium
*Outcome of CD autoimmunity has been considered the serological positivity of tTG antibodies.
BF, breast feeding; CD, celiac disease; NS, not significant; tTG, tissue transglutaminase.
6 Silano M, et al. BMJ Open 2016;6:e009163. doi:10.1136/bmjopen-2015-009163
Open Access
group.bmj.com on December 4, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
onset.30 Indeed, breast milk may independently prevent
intestinal infections, which are thought to be one of the
triggering factors for CD, modulate the intestinal micro-
biota, increasing the number of biﬁdobacteria, and
boost the mechanisms of oral tolerance by means of
several immunomodulatory molecules, offering a high
biological plausibility to the interpretation of a protect-
ive effect on immune-mediated diseases such as CD. No
studies are, at the moment, available to explain the lack
of a protective role of breast feeding on the risk of CD.
A recent study, however, revealed that breast milk of
mothers with CD has reduced concentrations of immu-
noprotective compounds (tumour growth factor (TGF)
-β1 and sIgA) and biﬁdobacteria 16S rRNA gene copy
numbers as compared with breast milk of healthy
mothers, which could presumably diminish the protect-
ive effects of breast feeding on the child’s future risk of
developing CD.31
A recent prospective study in a cohort of infants at
family risk of CD has shown that the HLA-DQ2/8 geno-
type may independently contribute to inﬂuencing the
composition of gut microbiota.7 32 In this regard, the
studies investigating the role of breast feeding on CD
development have included different control popula-
tions with heterogeneous genetic backgrounds, thereby
representing a non-controlled variable in most of them.
Additional environmental factors that could confound
the potential role of breast feeding on CD, directly or
via gut microbiota modulation, include mode of delivery,
incidence of infections and maternal diet.5 33 34 These
pieces of evidence suggest that a number of host and
environmental factors, besides gluten intake, might play
a relevant role in the onset of overt CD, thus confound-
ing the statistical analysis on the effect of breast feeding.
Time of gluten introduction and CD
It is quite clear from our analysis that the age of chil-
dren at exposure to gluten during the weaning process
bears no effect on CD development. Only two papers
found a correlation between the time of gluten introduc-
tion and development of CD. Norris et al15 found an
increased risk for both early and late gluten
Table 3 Effect of the time of gluten introduction on the development of CD
Reference Age of gluten introduction Effect size
GRADE
score
Bias
risk
Retrospective studies
Fälth-Magnusson et al19 Mean age at gluten
introduction:
6-month for CD cases
6.1 for controls
Range 4–7
Range 4–10
p NS
2 High
Peters et al23 Continuous risk per month
(1–12 months)
<3 vs >3 months
3 vs 4 months
4 vs 5 months
>5 months
HR 0.98 (95% CI 0.86 to 1.11)
HR 0.72 (95% CI 0.29 to 1.79)
HR 0.52 (95% CI 0.18 to 1.44)
HR 1.21 (95% CI 0.40 to 3.68)
HR 0.72 (95% CI 0.28 to 1.85)
1 High
Prospective studies
Ivarsson et al21 1–4 months
5–6 months (reference)
7–12 months
HR 1.4 (95% CI 0.87 to 2.4)
HR 0.76 (95% CI 0.41 to 1.4)
2 High
Ziegler et al14 <3 months
3–6 months (reference)
>6 months
HR 2.3 (95% CI 0.3 to 18.2)
HR 0.7 (95% CI 0.3 to 1.8)
3 Medium
Norris et al15 1–3 months
3–4 months (reference)
>7 months
HR 5.17 (95% CI 1.44 to
18.57)
HR 1.87 (95% CI 0.97 to 3.60)
3 Medium
Welander et al22 3–4 months
5–6 months (reference)
7–8 months
HR 1.0 (95% CI 0.3 to 3.3)
HR 1.1 (95% CI 0.6 to 2.0)
3 High
Størdal et al26 <4 months
5–6 months (reference)
>6 months
OR 1.27 (95% CI 1.01 to 1.65)
OR 1.05 (95% CI 0.69 to 1.58)
3 High
Jansen et al27 >6 months NS 3 Medium
Vriezinga et al13 16–24 weeks HR 1.23 (95% CI 0.79 to 1.91) 4 Low
Lionetti et al12 6 vs 12 months HR 0.9 (95% CI 0.6 to 1.4) 4 Low
Aronsson et al16 <17 weeks
17–26 (reference)
>26 weeks
HR 0.59 (95% CI 0.33 to 1.04)
HR 0.90 (95% CI 0.69 to 1.18)
3 Medium
CD, celiac disease; NS, not significant.
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introduction while Strødal et al26 reported an increased
risk for CD when gluten is introduced after 6 months of
age. It is noteworthy that these indices of risk are very
mild, with a large variation and a possible role of further
residual confounders, therefore showing only a low stat-
istical signiﬁcance. Both the two recent large, prospect-
ive studies demonstrated, with a very solid intervention
design, high GRADE score and low bias risk, that neither
early (4 months of age) nor late (1 year of age) intro-
duction of gluten impacts the later development of CD,
respectively.12 13 It is noteworthy that, in the Italian mul-
ticentre study, the group of baby girls (but not boys) at
high genetic risk of CD, carrying the DQ2 haplotypes in
homozygosis, who were introduced to gluten earlier (at
6 months)12 had a higher prevalence of CD even at
5 years of age. Similarly, in the multicentre European
trial,13 the girls (and again, not the boys) in the group
where gluten was introduced early (at 4 months) had a
higher prevalence of CD (21%) at 5 years of age than
those who were ﬁrst exposed to gluten at 6 months
(8.5%).
Also considering studies on food allergy, one study
(GINIplus and LISAplus) reported that a delayed intro-
duction of solid foods or the avoidance of highly aller-
genic foods during the ﬁrst year does not seem to be
beneﬁcial for allergy prevention, while only a very early
(before week 17 of age) introduction of solids may
increase the risk of later manifestations of eczema.35
Although CD has an obviously different pathogenetic
mechanism with respect to eczema, most epidemio-
logical studies support the hypothesis that, after the
fourth month of age, any solid can be safely introduced,
without increasing the risk of developing reactions to
food antigens.36 Accordingly, there is no reason to delay
the ﬁrst exposure to any solid food, including foods con-
sidered to be highly allergenic. Theoretically, the immu-
nodevelopmental processes and the generation of
regulatory T-cells and cytokines driving oral tolerance
are inﬂuenced by the structure of the microbiota colo-
nising the newborn intestine, which in turn evolves in
time mainly inﬂuenced by dietary changes, particularly
cessation of breast feeding and the introduction of
solids.37 38 Following these considerations, the timing of
gluten introduction suggested by the current ESPGHAN
commentary on complementary feeding appears out-
dated and is no longer evidence-supported, since it was
drafted before the publication of the studies reviewed
here.39
The Swedish observations on the celiac epidemic in
the late 80s, which occurred when the amount of gluten
given to infants during weaning was dramatically
increased, suggest that the amount of gluten itself might
have a key role.28 However, none of the studies suitable
for inclusion into a systematic review have collected
information about the load of gluten during the early
feeding phases. It is likely that the amount of gluten
introduced at weaning might play a pivotal role in trig-
gering CD in predisposed children. Information about
this issue might provide us an important clue to under-
stand how early feeding practices might inﬂuence CD
development. Studies about the role of varying amounts
of gluten given to infants during weaning are not avail-
able. Even observations reporting the Swedish epidemic
of CD that occurred after changes in infant feeding
practices fail to provide information about the actual
amount of gluten that was introduced to the involved
infants during weaning.
The generalisability of our results has been enhanced
by the involvement of children from both Europe and
the USA, and the uniformity of the diagnosis of CD,
made by means of the serum positive titre of anti-tTG
antibodies and duodenal biopsy.
On the other hand, most of the papers included in
our analysis have a high bias risk. Several papers
included controls from general populations not selected
for at-risk genetic background and others enrolled chil-
dren at genetic risk for T1DM, a condition partially
sharing the same type of genetic predisposition as CD.
Within these limits, all the studies that enrolled DQ2
+children, with a prospective design, are in agreement
that both breast feeding and the timing of gluten intro-
duction during weaning do not impact on the develop-
ment of CD.
The results of this systematic review are consistent
with those of a recent meta-analysis by Szajewska
et al,40 which has included the same studies. With
respect to that review, we scored the papers according
to their bias risk and discussed the results from a dif-
ferent angle, including the data that support a role for
additional variables in the development of CD, such as
differences in microbiota and breast milk composition.
On the contrary, the paper by Szajewska et al is
focused exclusively on the role of gluten introduction
into the diet.
In conclusion, there is currently no evidence to rec-
ommend avoiding either an early (at 4 months of age)
or a late (at or after 6 or even 12 months) gluten intro-
duction in children at risk of CD. The possible excep-
tion of DQ2 homozygous girls,12 13 where an early
introduction of gluten appears to be associated with a
greater risk of subsequent development of CD must,
however, be acknowledged, and requires further study,
possibly representing an early manifestation of ‘medi-
cine of gender’. Accordingly, no speciﬁc general recom-
mendations about gluten introduction or optimal
breastfeeding duration can be presently provided on
evidence-based criteria.
Even in the absence of evidence of the protective
effect of breast feeding, it must be reiterated that breast
feeding should be implemented whenever possible in all
infants, including those at genetic risk for CD, for its
many, well-documented beneﬁts, including its unique
role in maternal–infant bonding.
Further studies that include variables so far neglected
are needed to progress in the identiﬁcation of critical
factors and predictive models of CD development.
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